Filing Details
- Accession Number:
- 0001203311-23-000109
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-08 17:09:16
- Reporting Period:
- 2023-09-07
- Accepted Time:
- 2023-09-08 17:09:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1060736 | Seagen Inc. | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1361966 | B Vaughn Himes | 21823 30Th Drive Se Bothell WA 98021 | Chief Technical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-09-07 | 8,785 | $44.09 | 60,224 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-09-07 | 8,785 | $205.76 | 51,439 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2023-09-07 | 8,785 | $0.00 | 8,785 | $44.09 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
26,447 | 2024-08-26 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 119,471 | Indirect | by Trust |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a written plan, entered into on 11/29/22, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- Reflects sales of common stock executed in multiple transactions at prices ranging from $205.40 to $206.17. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Options vested at a rate of 25% on 8/26/15 and monthly thereafter until all the options were fully vested on 08/26/18.